首页> 外文学位 >Potentiation of bradykinin actions by angiotensin I converting enzyme inhibitors.
【24h】

Potentiation of bradykinin actions by angiotensin I converting enzyme inhibitors.

机译:血管紧张素Ⅰ转化酶抑制剂增强缓激肽作用。

获取原文
获取原文并翻译 | 示例

摘要

The goal of our research was to understand better the mechanism behind the clinical benefits of angiotensin I converting enzyme (ACE) inhibitors, used by now in 5-10 million people world wide for the treatment of cardiovascular diseases. Many of the benefits of ACE inhibitor therapy in heart diseases are attributed to their effects in augmenting bradykinin (BK) activity. We tested the hypothesis that ACE inhibitors potentiate BK effects by a mechanism which is in addition to, and independent of the inhibition of BK degradation. We employed 3 preparations: the guinea pig ileum, guinea pig left atrium, and cultured Chinese hamster ovary (CHO) cells transfected with human cDNAs encoding the BK {dollar}rm Bsb2{dollar} receptor with and without somatic ACE.; In the guinea pig ileum, BK effects were potentiated immediately although the peptide was inactivated slowly. ACE inhibitors potentiated BK effects even after ACE was inactivated by sequestering the {dollar}rm Znsp{lcub}2+{rcub}{dollar} cofactor of the enzyme, and BK analogues which are hydrolyzed much slower than BK, such as dextran-BK and methionyl-lysyl-BK, were also potentiated by ACE inhibitors, suggesting that an alternative BK potentiating mechanism exists. This mechanism was further examined on guinea pig atria another ACE-resistant analogue, {dollar}rmlbrack Hypsp3{dollar}-{dollar}rm Tyr(Me)sp8rbrack {dollar}-BK. Enalaprilat not only increased the maximum and steady-state inotropic effects of the kinin analogue but actually restored the positive inotropic response after it very much decreased because the continued presence of the agonist desensitized the receptor. Thus, enalaprilat inhibited desensitization and reactivated the receptor. To determine whether ACE inhibitors interact directly with the BK {dollar}rm Bsb2{dollar}-receptor when potentiating BK, we measured receptor binding and agonist-stimulated responses (inositol 1,4,5-trisphosphate generation and {dollar}rmlbrack sp3Hrbrack {dollar}arachidonic acid release) in CHO cells expressing only the {dollar}rm Bsb2{dollar}-receptor but saw enalaprilat had no effect in the system. However, when in cells ACE and the B{dollar}sb2{dollar}-receptor were co-expressed, enalaprilat inhibited B{dollar}sb2{dollar}-receptor desensitization and internalization, and potentiated functional responses. Thus, the data indicate a novel hypothesis whereby ACE inhibitors, indirectly via ACE, potentiate and sustain the actions of BK by reactivating or maintaining the active conformation of the BK {dollar}rm Bsb2{dollar}-receptor.
机译:我们研究的目的是更好地了解血管紧张素I转换酶(ACE)抑制剂的临床益处背后的机制,该抑制剂目前已在全球5-10百万人中用于治疗心血管疾病。 ACE抑制剂治疗心脏病的许多好处归因于其增强缓激肽(BK)活性的作用。我们测试了以下假设:ACE抑制剂通过除BK降解抑制作用之外的机制来增强BK作用。我们采用了3种制剂:豚鼠回肠,豚鼠左心房,以及培养的中国仓鼠卵巢(CHO)细胞,该细胞被编码有或没有体质ACE的BK {rmal} rm Bsb2 {dolal}受体的人cDNA转染。在豚鼠回肠中,尽管该肽缓慢失活,但BK效应立即增强。 ACE抑制剂甚至可以通过螯合酶的{rm} rm Znsp {lcub} 2+ {rcub} {dol}辅因子以及水解速度比BK慢得多的BK类似物(例如右旋糖酐BK)来增强ACE的BK效果。 ACE抑制剂也可增强甲硫基和赖氨酰-甲硫基-赖氨酰-BK的浓度,这表明存在替代的BK增强作用机制。在豚鼠心房上进一步研究了这种机制,即另一种抗ACE的类似物,即Tyr(Me)sp8rbrack(美元)-BK。依那普利拉不仅增加激肽类似物的最大和稳态正性肌力作用,而且由于激动剂的持续存在使受体脱敏,因此在其大大降低后实际上恢复了正性肌力反应。因此,依那普利拉抑制脱敏并重新激活受体。为了确定增效BK时ACE抑制剂是否与BK {rm} rm Bsb2 {dol}受体直接相互作用,我们测量了受体结合和激动剂刺激的响应(肌醇1,4,5-三三磷酸生成和{r} rmlbrack sp3Hrbrack {在仅表达{dol} rm Bsb2 {dollar}-受体的CHO细胞中释放出美元}花生四烯酸,但发现依那普利拉对系统没有影响。然而,当在细胞中ACE和B {sdol2}受体共同表达时,依那普利拉抑制了Bs1受体的脱敏和内在化,并增强了功能反应。因此,数据表明了一种新的假设,即ACE抑制剂通过ACE间接地通过重新激活或维持BK {rm} rm Bsb2 {dol}受体的活性构象来增强和维持BK的作用。

著录项

  • 作者

    Minshall, Richard Dale.;

  • 作者单位

    University of Illinois at Chicago, Health Sciences Center.;

  • 授予单位 University of Illinois at Chicago, Health Sciences Center.;
  • 学科 Health Sciences Pharmacology.; Biology Cell.
  • 学位 Ph.D.
  • 年度 1997
  • 页码 113 p.
  • 总页数 113
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药理学;细胞生物学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号